Table 1.
Clinical trials demonstrating the efficacy of alemtuzumab in patients with CLL that was either relapsed or refractory to fludarabine and/or alkylating agents
RR indicates response rate; CR, complete remission; PR, partial remission; PFS, progression-free survival; OS, overall survival; NA, not applicable.
*Study included CLL, prolymphocytic leukemia, and other chronic lymphoproliferative disorders; response rate is for CLL.
